MiR-138 is a potent regulator of the heterogenous MYC transcript population in cancers

MiR-138 是癌症中异质性 MYC 转录本群的强效调节剂

阅读:22
作者:Ng Desi, Velda Teh, Qing Yun Tong, Chun You Lim, Hossein Tabatabaeian, Xiao Hong Chew, Avencia Sanchez-Mejias, Jia Jia Chan, Bin Zhang, Priyankaa Pitcheshwar, Bei-En Siew, Shi Wang, Kuok-Chung Lee, Choon-Seng Chong, Wai-Kit Cheong, Bettina Lieske, Ian Jse-Wei Tan, Ker-Kan Tan, Yvonne Tay

Abstract

3'UTR shortening in cancer has been shown to activate oncogenes, partly through the loss of microRNA-mediated repression. This suggests that many reported microRNA-oncogene target interactions may not be present in cancer cells. One of the most well-studied oncogenes is the transcription factor MYC, which is overexpressed in more than half of all cancers. MYC overexpression is not always accompanied by underlying genetic aberrations. In this study, we demonstrate that the MYC 3'UTR is shortened in colorectal cancer (CRC). Using unbiased computational and experimental approaches, we identify and validate microRNAs that target the MYC coding region. In particular, we show that miR-138 inhibits MYC expression and suppresses tumor growth of CRC and hepatocellular carcinoma (HCC) cell lines. Critically, the intravenous administration of miR-138 significantly impedes MYC-driven tumor growth in vivo. Taken together, our results highlight the previously uncharacterized shortening of the MYC 3'UTR in cancer, and identify miR-138 as a potent regulator of the heterogenous MYC transcript population.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。